Spirito, P, Autore, C, Formisano, F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol 2014; 113: 1550–1555.
Veselka, J, Zemánek, D, Jahnlová, D, et al. Risk and causes of death in patients after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol 2015; 31: 1245–1251.
Maron, BJ, Rowin, EJ, Casey, SA, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 2015; 65: 1915–1928.
Pascoe, SJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018; 379: 1976–1977.
Walsh, R, Buchan, R, Wilk, A, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J 2017; 38: 3461–3468.
Walsh, R, Thomson, KL, Ware, JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med 2017; 19: 192–203.
Akhtar, M, Elliott, P. The genetics of hypertrophic cardiomyopathy. Glob Cardiol Sci Pract 2018; 2018: 36.
Marian, AJ, Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121: 749–770.
Liew, AC, Vassiliou, VS, Cooper, R, Raphael, CE. Hypertrophic cardiomyopathy-past, present and future. J Clin Med 2017; 6: 118.
Bamshad, MJ, Ng, SB, Bigham, AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12: 745–755.
Leproust, E. Target enrichment strategies for next generation sequencing. Mlo Med Lab Obs 2012; 44: 26–27.
Petersen, BS, Fredrich, B, Hoeppner, MP, Ellinghaus, D, Franke, A. Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet 2017; 18: 14.
Rayment, I, Holden, HM, Sellers, JR, Fananapazir, L, Epstein, ND. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 1995; 92: 3864–3868.
Woo, A, Rakowski, H, Liew, JC, et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 2003; 89: 1179–1185.
Elliott, PM, Anastasakis, A, Borger, MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733–2779.
Richards, S, Aziz, N, Bale, S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 2015; 17: 405–424.
Carrier, L, Mearini, G, Stathopoulou, K, Cuello, F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene 2015; 573: 188–197.
Sakamoto, N, Kawamura, Y, Sato, N, et al. Late gadolinium enhancement on cardiac magnetic resonance represents the depolarizing and repolarizing electrically damaged foci causing malignant ventricular arrhythmia in hypertrophic cardiomyopathy. Heart Rhythm 2015; 12: 1276–1284.
Charron, P, Dubourg, O, Desnos, M, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998; 97: 2230–2236.
Niimura, H, Bachinski, LL, Sangwatanaroj, S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338: 1248–1257.
Erdmann, J, Raible, J, Maki-Abadi, J, et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001; 38: 322–330.
Gilbert, R, Kelly, MG, Mikawa, T, Fischman, DA. The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Sci 1996; 109 (Pt 1): 101–111.
Gilbert, R, Cohen, JA, Pardo, S, Basu, A, Fischman, DA. Identification of the A-band localization domain of myosin binding proteins C and H (MyBP-C, MyBP-H) in skeletal muscle. J Cell Sci 1999; 112 (Pt 1): 69–79.
Freiburg, A, Gautel, M. A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Eur J Biochem 1996; 235: 317–323.
Monteiro, DRA, Guerrero-Serna, G, Helms, A, et al. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. J Mol Cell Cardiol 2016; 99: 197–206.
Prondzynski, M, Mearini, G, Carrier, L. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. Pflugers Arch 2019; 471: 807–815.
Hammond, SM, Wood, MJ. Genetic therapies for RNA mis-splicing diseases. Trends Genet 2011; 27: 196–205.
Gedicke-Hornung, C, Behrens-Gawlik, V, Reischmann, S, et al. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. Embo Mol Med 2013; 5: 1128–1145.
Garcia-Giustiniani, D, Arad, M, Ortiz-Genga, M, et al. Phenotype and prognostic correlations of the converter region mutations affecting the beta myosin heavy chain. Heart 2015; 101: 1047–1053.